EGFR and lung adenocarcinoma: For example, a study measuring change in FLT SUVmax between baseline and after 7 days of gefitinib therapy in participants with EGFR-mutant lung adenocarcinoma found that responders (as defined on CT evaluation at 6 wk) had a significantly different change in SUVmax than nonresponders (−36% ± 15% versus 10% ± 20%, respectively, p < 0.001).28